The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Open accessAbstract
Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c) graft-versus-host disease (GVHD) cause high mortality. Preclinical evidence indicates the potent anti-inflammatory properties of the JAK1/2 inhibitor ruxolitinib. In this retrospective survey, 19 stem cell transplant centers in Europe and the United States reported outcome data from 95 patients who had received ruxolitinib as salvage therapy for SR-GVHD. Patients were classified as having SR-aGVHD (n=54, all grades III or IV) or SR-cGVHD (n=41, all moderate or severe). The median number of previous GVHD-therapies was 3 for both SR-aGVHD (1–7) and SR-cGVHD (1–10). The overall response rate was 81.5% (44/54) in SR-aGVHD including 25 complete responses (46.3%), while for SR-cGVHD the ORR was 85.4% (35/41). Of those patients responding to ruxolitinib, the rate of GVHD-relapse was 6.8% (3/44) and 5.7% (2/35) for SR-aGVHD and SR-cGVHD, respectively. The 6-month-survival was 79% (67.3–90.7%, 95% confidence interval (CI)) and 97.4% (92.3–100%, 95% CI) for SR-aGVHD and SR-cGVHD, respectively. Cytopenia and cytomegalovirus-reactivation were observed during ruxolitinib treatment in both SR-aGVHD (30/54, 55.6% and 18/54, 33.3%) and SR-cGVHD (7/41, 17.1% and 6/41, 14.6%) patients. Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
1994 Consensus Conference on Acute GVHD Grading.
Przepiorka, D., Weisdorf, D., Martin, P., Hg, K., Beatty, P., Hows, J., & Thomas, E. D. (1995) · PubMed · Cited by 5,037
Filipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.004 · Cited by 3,556
Szer, J. (1999) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb127745.x · Cited by 3,353
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108188 · Cited by 1,119
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
Martin, P. J., Rizzo, J. D., Wingard, J. R., Ballen, K., Curtin, P. T., Cutler, C., Litzow, M. R., Nieto, Y., Savani, B. N., Schriber, J. R., et al. (2012) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.04.005 · Cited by 641
Lerner, K. G., Kao, G. F., Storb, R. F., Buckner, C. D., Ra, C., & Thomas, E. D. (1974) · PubMed · Cited by 454
Rituximab for steroid-refractory chronic graft-versus-host disease
Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S.-B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C., et al. (2006) · Blood · doi:10.1182/blood-2006-01-0233 · Cited by 452
Kremer, J., Li, Z.-G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J. D., Gruben, D., Wallenstein, G., Krishnaswami, S., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00006 · Cited by 448
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Spoerl, S., Mathew, N. R., Bscheider, M., Schmitt-Graeff, A., Chen, S., Mueller, T., Verbeek, M., Fischer, J., Otten, V., Schmickl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-12-543736 · Cited by 401
Self-citationThe JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Heine, A., Held, S. A. E., Daecke, S. N., Wallner, S., Yajnanarayana, S. P., Kurts, C., Wolf, D., & Brossart, P. (2013) · Blood · doi:10.1182/blood-2013-03-484642 · Cited by 344
Self-citationSchwab, L., Goroncy, L., Palaniyandi, S., Gautam, S., Triantafyllopoulou, A., Mocsai, A., Reichardt, W., Karlsson, F. J., Radhakrishnan, S. V., Hanke, K., et al. (2014) · Nature Medicine · doi:10.1038/nm.3517 · Cited by 302
Self-citationGreinix, H. T., Volc-Platzer, B., Kalhs, P., Fischer, G., Rosenmayr, A., Keil, F., Hönigsmann, H., & Knobler, R. M. (2000) · Blood · doi:10.1182/blood.v96.7.2426 · Cited by 228
Steroid-Refractory Acute GVHD: Predictors and Outcomes
Westin, J. R., Saliba, R. M., De Lima, M., Alousi, A., Hosing, C., Qazilbash, M. H., Khouri, I. F., Shpall, E. J., Anderlini, P., Rondon, G., et al. (2011) · Advances in Hematology · doi:10.1155/2011/601953 · Cited by 217
Flynn, R., Du, J., Veenstra, R. G., Reichenbach, D. K., Panoskaltsis-Mortari, A., Taylor, P. A., Freeman, G. J., Serody, J. S., Murphy, W. J., Munn, D. H., et al. (2014) · Blood · doi:10.1182/blood-2014-03-562231 · Cited by 215
Self-citationNicholson, S. E., Oates, A. C., Harpur, A. G., Ziemiecki, A., Wilks, A. F., & Layton, J. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.2985 · Cited by 201
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1
Benito, A. I., Furlong, T., Martin, P. J., Anasetti, C., Appelbaum, F. R., Doney, K., Nash, R. A., Papayannopoulou, T., Storb, R., Sullivan, K. M., et al. (2001) · Transplantation · doi:10.1097/00007890-200112270-00010 · Cited by 184
Gor, D., Sabin, C., Prentice, H., Vyas, N., Man, S., Griffiths, P., & Emery, V. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701139 · Cited by 180
The best endpoint for acute GVHD treatment trials
MacMillan, M. L., DeFor, T. E., & Weisdorf, D. J. (2010) · Blood · doi:10.1182/blood-2009-12-258442 · Cited by 159
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment
Arai, S., Margolis, J., Zahurak, M., Anders, V., & Vogelsang, G. B. (2002) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2002.v8.pm11939605 · Cited by 159
Bucher, C., Koch, L., Vogtenhuber, C., Goren, E. M., Munger, M. E., Panoskaltsis-Mortari, A., Sivakumar, P., & Blazar, B. (2009) · Blood · doi:10.1182/blood-2009-05-221135 · Cited by 156
Self-citationAssociation of Serum Interleukin-7 Levels With the Development of Acute Graft-Versus-Host Disease
Dean, R. M., Fry, T. J., Mackall, C. L., Steinberg, S. M., Hakim, F. T., Fowler, D. H., Odom, J., Foley, J., Gress, R. E., & Bishop, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1314 · Cited by 92
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease
Hoda, D., Pidala, J., Salgado-Vila, N., Kim, J., Perkins, J. B., Bookout, R., Field, T. L., Perez, L. E., Ayala, E., Ochoa-Bayona, J. L., et al. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.343 · Cited by 76
Boome, L. C. J. T., Mansilla, C., van der Wagen, L. E., Lindemans, C. A., Petersen, E. J., Spierings, E., Thus, K. A., Westinga, K., Plantinga, M., Bierings, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.89 · Cited by 76
Self-citationTherapeutic activity of multiple common γ-chain cytokine inhibition in acute and chronic GVHD
Hechinger, A.-K., Smith, B. A. H., Flynn, R. P., Hanke, K., McDonald-Hyman, C. S., Taylor, P. A., Pfeifer, D., Hackanson, B. W., Leonhardt, F., Prinz, G., et al. (2014) · Blood · doi:10.1182/blood-2014-06-581793 · Cited by 76
Self-citationHe, Y.-W., Adkins, B., Furse, R. K., & Malek, T. R. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.4.1596 · Cited by 70
Giroux, M., Delisle, J., Gauthier, S.-D., Heinonen, K. M., Hinsinger, J., Houde, B., Gaboury, L. A., Brochu, S., Wu, J., Hébert, M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-287649 · Cited by 45
Rapamycin for Refractory Acute Graft-Versus-Host Disease
Ghez, D., Rubio, M., Maillard, N., Suárez, F., Chandesris, M., Delarue, R., Deau, B., Varet, B. R., Hermine, O., & Buzyn, A. (2009) · Transplantation · doi:10.1097/tp.0b013e3181ba0a13 · Cited by 35
Mielke, S., Lutz, M., Schmidhuber, J., Kapp, M., Ditz, D., Ammer, J., Einsele, H., Grigoleit, G. U., Holler, E., & Wolff, D. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.170 · Cited by 26
Self-citation
Cited by
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1609337 · Cited by 1,296
Self-citationRuxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
Zeiser, R., von Bubnoff, N., Butler, J., Mohty, M., Niederwieser, D., Or, R., Szer, J., Wagner, E. M., Zuckerman, T., Mahuzier, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917635 · Cited by 881
Self-citationPathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748
Self-citationJAK inhibitors in dermatology: The promise of a new drug class
Damsky, W., & King, B. A. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.12.005 · Cited by 530
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
Zeiser, R., Polverelli, N., Ram, R., Hashmi, S. K., Chakraverty, R., Middeke, J. M., Musso, M., Giebel, S., Uzay, A., Langmuir, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033122 · Cited by 527
Self-citation
Metadata
- Authors
- Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I.-K., Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Lübbert, M., Wäsch, R., Scheid, C., Stölzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Gräff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kröger, N., Passweg, J., Halter, J., Socié, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J., & von Bubnoff, N.
- Venue
- Leukemia
- Published
- 2015-07-31
- Volume
- 29
- Issue
- 10
- Pages
- 2062-2068
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W1870543278
- Cited by
- 539
- References
- 33
- FWCI
- 36.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.